

AngioDynamics to Hold Fiscal 2006 Fourth Quarter Financial Results Conference Call on Thursday, August 10, 2006

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Aug. 1, 2006--AngioDynamics, Inc. (NASDAQ:ANGO) today announced that the company will release fiscal 2006 fourth quarter results after the market closes on Thursday, August 10, 2006.

Eamonn P. Hobbs, president and chief executive officer, and Joseph G. Gerardi, chief financial officer, will host an investment community conference call beginning at 4:30 p.m. Eastern Time on August 10th to discuss these results and to answer questions.

To participate in the live call by telephone, please dial (800) 435-1261 from the U.S., or for international callers, please dial (617) 614-4076. Please enter the passcode: 49465846.

Those interested in listening to the conference call live via the Internet may do so by visiting the Investor Relations section of AngioDynamics' Web site at <http://investor.angiodynamics.com/>. To listen to the live call, please go to the Web site 15 minutes prior to its start to register, download, and install the necessary audio software.

A replay will be available on the Web site. A telephone replay will be available from 6:30 p.m. Eastern Time on August 10, 2006 through 11:59 p.m. Eastern Time on August 17 by dialing (888) 286-8010 (domestic) or (617) 801-6888 (international) and entering the passcode: 80055295.

About AngioDynamics

AngioDynamics, Inc. (www.angiodynamics.com) is a leading provider of innovative medical devices used by interventional radiologists, vascular surgeons and other physicians for the minimally invasive diagnosis and treatment of peripheral vascular disease. AngioDynamics, Inc. designs, develops, manufactures and markets a broad line of therapeutic and diagnostic devices that enable interventional physicians, such as interventional radiologists, vascular surgeons and others, to treat peripheral vascular diseases and other non-coronary diseases. The Company's diverse product line includes angiographic products and accessories, dialysis products, vascular access products, thrombolytic products, venous system products, PTA products, and drainage products.

The statements made in this document contain certain forward-looking statements that involve a number of risks and uncertainties. Words such as "expects," "intends," "anticipates," "plans," "believes," "seeks," "estimates," or variations of such words and similar expressions, are intended to identify such forward-looking statements. Investors are cautioned that actual events or results may differ from the Company's expectations. In addition to the matters described above, the ability of the Company to develop its products, future actions by the FDA or other regulatory agencies, results of any future clinical trials, results of pending patent litigation and the Company's ability to protect its intellectual property, overall economic conditions, general market conditions, market acceptance, inadequate reimbursement from third party payers, effects of healthcare reform and competition as well as the risk factors listed from time to time in the SEC filings of AngioDynamics, Inc., including but not limited to its Annual Report on Form 10-K for the year ended May 28, 2005, may affect the actual results achieved by the Company.

CONTACT: AngioDynamics, Inc.
Joe Gerardi, 800-772-6446 x115
www.AngioDynamics.com
or
Investor Relations Contacts:
Lippert/Heilshorn & Associates, Inc.
Kim Sutton Golodetz, 212-838-3777
kgolodetz@lhai.com
Bruce Voss, 310-691-7100
bvoss@lhai.com

SOURCE: AngioDynamics, Inc.